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ABSTRACT
Background
Somatic genetic CDKN2A, TP53, and DNA content abnormalities are common in many human
cancers and their precursors, including esophageal adenocarcinoma (EA) and Barrett’s
esophagus (BE), conditions for which aspirin and other nonsteroidal anti-inflammatory drugs
(NSAIDs) have been proposed as possible chemopreventive agents; however, little is known
about the ability of a biomarker panel to predict progression to cancer nor how NSAID use may
modulate progression. We aimed to evaluate somatic genetic abnormalities with NSAIDs as
predictors of EA in a prospective cohort study of patients with BE.
Methods and Findings
Esophageal biopsies from 243 patients with BE were evaluated at baseline for TP53 and
CDKN2A (p16) alterations, tetraploidy, and aneuploidy using sequencing; loss of heterozygosity
(LOH); methylation-specific PCR; and flow cytometry. At 10 y, all abnormalities, except CDKN2A
mutation and methylation, contributed to EA risk significantly by univariate analysis, ranging
from 17p LOH (relative risk [RR]¼ 10.6; 95% confidence interval [CI] 5.2–21.3, p , 0.001) to 9p
LOH (RR ¼ 2.6; 95% CI 1.1–6.0, p ¼ 0.03). A panel of abnormalities including 17p LOH, DNA
content tetraploidy and aneuploidy, and 9p LOH was the best predictor of EA (RR ¼ 38.7; 95%
CI 10.8–138.5, p , 0.001). Patients with no baseline abnormality had a 12% 10-y cumulative EA
incidence, whereas patients with 17p LOH, DNA content abnormalities, and 9p LOH had at least
a 79.1% 10-y EA incidence. In patients with zero, one, two, or three baseline panel
abnormalities, there was a significant trend toward EA risk reduction among NSAID users
compared to nonusers (p¼0.01). The strongest protective effect was seen in participants with
multiple genetic abnormalities, with NSAID nonusers having an observed 10-y EA risk of 79%,
compared to 30% for NSAID users (p , 0.001).
Conclusions
A combination of 17p LOH, 9p LOH, and DNA content abnormalities provided better EA risk
prediction than any single TP53, CDKN2A, or DNA content lesion alone. NSAIDs are associated
with reduced EA risk, especially in patients with multiple high-risk molecular abnormalities.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org February 2007 | Volume 4 | Issue 2 | e67 0342
PLoS MEDICINEIntroduction
Rapid advances in understanding the molecular patho-
genesis of neoplasia have raised the possibility that molecular
abnormalities may be used as ‘‘biomarkers’’ for cancer risk
stratiﬁcation and early detection as well as possible entry
criteria for cancer-prevention trials [1–4]. Identiﬁcation of
inherited, highly penetrant mutations in some cancer-
susceptibility genes is being incorporated into clinical
practice as well as cancer-prevention strategies for patients
with many familial cancer syndromes, including inherited
breast cancer, hereditary nonpolyposis colon cancer, and
adenomatous polyposis coli [5–10]. Although progress in
developing predictive biomarkers from common somatic
genetic abnormalities in at-risk tissues has been less striking,
there is some evidence that this approach may be successful.
Based on a genetic progression model for head and neck
cancer [11,12], a series of retrospective, longitudinal studies
have been performed on patients with the premalignant
condition oral leukoplakia, resulting in potential biomarker
panels for risk stratiﬁcation [13–16]. Some of these bio-
markers have been proposed as entry criteria for a
randomized cancer-prevention trial using cyclo-oxygenase-2
and epidermal growth factor receptor inhibitors [4]. Under-
standing how modiﬁable exposures interact with the somatic
genetic composition of a neoplasm will be important for
individualized interventions and cancer prevention.
Barrett’s esophagus (BE) is a premalignant condition that
predisposes to esophageal adenocarcinoma (EA). The inci-
dence of this cancer has risen dramatically in the United
States, Western Europe, Australia, and other developed
countries over the past three decades, with little sign of
abating [17,18]. Unfortunately, EA is typically lethal unless
detected early, having an overall survival rate of only 13.7%
[19]. Endoscopic surveillance is recommended for early
detection in BE [20], and there has been recent interest in
the potential for cancer prevention using nonsteroidal anti-
inﬂammatory drugs (NSAIDs) based on data from case
control and cohort studies [21–25], as well as preclinical
models [26,27]. Analysis of genetic progression of BE has
identiﬁed abnormalities in the tumor-suppressor genes TP53
and CDKN2A, as well as DNA content abnormalities (tetra-
ploidy and aneuploidy) as critical events in the evolution of
EA [28–40]. Several prospective studies have suggested that
individual somatic genetic abnormalities derived from this
progression model may identify those patients with BE who
are at increased risk for progression to EA, but no study has
evaluated the combined contributions of genetic abnormal-
ities for EA risk prediction [34,41–45].
Using data collected prospectively over a 10-y period from a
long-standingcohortstudyofpatientswithBE,weinvestigated
the role of host factors in combination with somatic genetic
abnormalities in the development of EA. The aims of the study
were to determine whether somatic genetic abnormalities
involving TP53,CDKN2A, and DNA content were predictors of
progression to EA and whether regular NSAID use modulates
risk of these abnormalities for future EA.
Methods
Study Design
This was a prospective, longitudinal study of the Seattle
Barrett’s Esophagus Study cohort. It constituted a phase 4
study according to the National Cancer Institute’s Early
Detection Research Network classiﬁcation [3]. The Seattle
Barrett’s Esophagus Study was approved by the Human
Subjects Division of the University of Washington in 1983 and
was renewed annually thereafter with reciprocity from the
Institutional Review Board of the Fred Hutchinson Cancer
Research Center from 1993 to 2001. Since 2001, the study has
been approved annually by the Institutional Review Board of
the Fred Hutchinson Cancer Research Center with reci-
procity from the Human Subjects Division of the University
of Washington.
Participants
Two hundred and seventy-four participants were eligible as
deﬁned by a diagnosis of metaplastic columnar epithelium
with intestinal metaplasia in esophageal biopsies, the absence
of esophageal malignancy at or prior to baseline endoscopy,
and having had at least one follow-up endoscopy. Two
hundred and forty-three participants had sufﬁcient tissue
for ﬂow cytometry, mutation, and LOH analysis in the same
DNA samples and represented the ﬁnal study cohort. Study
participants entered surveillance from 1983 to 1999 (Table 1).
The baseline endoscopy was deﬁned as the ﬁrst endoscopy
from 5 January 1995 to 2 December 1999. Since this is a long-
standing cohort, we assessed the enrollment-time effect by
performing statistical analyses with all patients, and also with
the subset of 211 patients, excluding the 32 patients who
entered the cohort before 1990, and found no change in the
conclusions of the study. This study was conducted at a
specialty research and referral center, and thus our cohort is
considered a high-risk patient population. We included all
cancers that developed subsequent to the baseline evaluation
so that accurate risk-stratiﬁcation models could be developed
based on ﬁndings at a single baseline endoscopy [44].
All research participants were counseled concerning the
risks and beneﬁts of endsocopic biopsy surveillance for BE.
Patients with high-grade dysplasia (HGD) were also counseled
concerning the risks and beneﬁts of esophagectomy and
endoscopic therapies. Endoscopic biopsy protocols used in
the Seattle Barrett’s Esophagus Study have been published
Table 1. Cohort Characteristics
Characteristic Group Number Percentage
Year entered cohort
a Pre-1990 32 13
1990–1994 40 16
1995–1999 171 70
Sex Male 189 78
Female 54 22
Age (y) 30–44 18 7
45–54 50 21
55–64 56 23
65–74 78 32
 75 41 17
Barrett’s segment length (cm) ,35 4 2 2
3–6 99 41
7–10 68 28
.10 22 9
n ¼ 243.
aBaseline endoscopy defined as first endoscopy after 1 January 1995.
doi:10.1371/journal.pmed.0040067.t001
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for biomarkers every 2 cm in the Barrett’s segment regardless
of histologic diagnosis. In patients without HGD, four-
quadrant biopsies were obtained for histologic evaluation
every 2 cm in the Barrett’s segment. If, after fully informed
consent, participants with HGD opted for endoscopic biopsy
surveillance reserving intervention for cancer if detected,
they were evaluated by an intensive protocol of four-
quadrant biopsies every 1 cm in the Barrett’s epithelium at
closely timed intervals for 4 mo, after which time endoscopies
were typically repeated approximately every 6 mo [47].
Exclusion of patients who were diagnosed with EA that
developed within 4 mo of their baseline procedure (n¼4) did
not alter the conclusions of the study. Participants with
maximum baseline diagnosis of HGD had an average of 7.3
endoscopies (median ¼ 6.5, range 2–18), compared to those
with less HGD at baseline, who had an average of 4.8
endoscopies (median ¼ 4, range 2–20).
The cohort is typical for gender, age, and Barrett’s segment
length compared to other specialty research centers (Table 1)
[48–51]. The cohort included 189 males and 54 females with a
mean age of 62 y (median¼64 y, range 30–87 y) at entry into
the study. This cohort was comprised of participants with
maximum baseline histologic diagnoses including negative
for dysplasia (n ¼ 67), indeﬁnite (n ¼ 78), low-grade dysplasia
(n ¼ 48), and HGD (n ¼ 50) using previously published
pathology criteria [43,52]. The mean Barrett’s segment length,
deﬁned by total centimeters between the ora serrata and the
distal end of the tubular esophagus proximal to the ﬂattening
of the gastric folds, was 5.6 cm (median ¼ 5 cm, range 0–20
cm). Participants were followed for a total of 17,139 patient-
months with a mean of 71 mo (median ¼ 80.5 mo, range 2.3–
130.8 mo).
Endoscopy and Biopsy
Endoscopy and biopsy were performed using a standard
protocol [43]. Participants with a history of HGD (n¼50) had
histologic evaluation of four-quadrant biopsies at 1-cm
intervals in the Barrett’s segment, whereas those without a
history of HGD (n ¼ 193) had histologic analysis of four-
quadrant biopsies at 2-cm intervals. Histologic analyses were
evaluated in biopsies obtained at the baseline evaluation and
at all follow-up endoscopies, whereas TP53, CDKN2A, and
DNA content analyses were evaluated at a single baseline
endoscopy. For each baseline endoscopy, samples were
characterized for 17p LOH spanning TP53, TP53 mutations,
DNA content abnormalities including tetraploidy and aneu-
ploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A
promoter methylation, and CDKN2A mutation in one biopsy
every 2 cm in the Barrett’s segment (average¼3.2, range 1–11
biopsies analyzed per study participant). For a participant to
be counted as having a molecular abnormality at baseline, the
abnormality must have been detected in more than one ﬂow-
puriﬁed DNA fraction or in a single sample that has been
conﬁrmed in a second, independent reaction.
Flow Cytometry
Biopsies were processed by DNA content (DAPI) and Ki67/
DNA content ﬂow cytometry to determine 4N fraction and
ploidy, and to purify proliferating cells using previously
validated techniques [43,45,53]. Flow-puriﬁed fractions are
deﬁned as Ki67-positive (proliferating) 2N, 4N, increased 4N/
tetraploid (cells with DNA content between 3.85 and 4.10N
that comprise .6% of the total cells), and aneuploid
populations (distinct DNA content peak representing
.2.5% of cells). Cell-cycle analysis was performed on 1,569
ﬂow-puriﬁed fractions with a median of 6.5 (range 1–29) cell-
cycle fractions depending on Barrett’s segment length.
DNA Extraction, Whole-Genome Amplification and LOH
Analysis
DNA was extracted from ﬂow-puriﬁed cell populations
using either standard phenol/chloroform or the Puregene
DNA Isolation Kit as recommended by the manufacturer
(Gentra Systems, Minneapolis, Minnesota, United States).
Whole-genome ampliﬁcation using primer extension pream-
pliﬁcation was performed with each sorted fraction and three
constitutive controls per participant [53]. LOH data was
obtained from 1,331 and 1,284 ﬂow-puriﬁed fractions at 17p
and 9p loci, respectively, as detailed previously [34,44,53].
Thirteen microsatellite loci were evaluated, including the 17p
loci D17S1298 (3.87 Mbp), D17S1537 (6.10 Mbp), TP53-ALU
(AAAAT)n in intron 1 (7.77 Mbp), TP53 (CA)n (7.77 Mbp),
D17S786 (9.01 Mbp), D17S974 (10.72 Mbp), D17S1303 (11.06
Mbp), and Chromosome 9p loci D9S2169 (5.19 Mbp), D9S935
(5.19 Mbp), D9S925 (18.28 Mbp), D9S932 (24.43 Mbp),
D9S1121 (25.39 Mbp), and D9S1118 (31.92 Mbp). Physical
map locations were determined from the University of
California, Santa Cruz (Santa Cruz, California, United States)
version hg16 July 2003 assembly (http://genome.cse.ucsc.edu).
LOH was deﬁned as Q
LOH   0.4 or   2.5 for loss which
spanned TP53 or CDKN2A [34,44,53]. For convenience, we
used the nomenclature of 17p LOH and 9p LOH to describe
LOH events spanning these genes. LOH was not scored for
rare telomeric or centomeric loss events that did not span
TP53 or CDKN2A. 17p LOH for all participants and 9p LOH
in HGD patients have been previously published [34,44].
CDKN2A Promoter Methylation Analysis
Genomic DNA from ﬂow-puriﬁed Barrett’s epithelium was
evaluated for CDKN2A promoter methylation in 175 ﬂow-
puriﬁed fractions from 121 participants. Only a subset (n ¼
121) of the patients had CDKN2A methylation tested because
the bisulﬁte treatment assays used required large amounts of
DNA, and the DNA from our ﬂow-puriﬁed fractions was
insufﬁcient for all molecular assays to be performed. This
patient subset was representative of the entire 243-patient
cohort with no statistically signiﬁcant difference in follow-up
time, sex, age, segment length, and cancer outcome between
the methylation-assayed group and the non-assayed group.
DNA was bisulﬁte treated and methylation-speciﬁc PCR was
performed with modiﬁcationsa sd e t a i l e dp r e v i o u s l y
[31,54,55]. Human genomic DNA treated in vitro with Sss I
methyltransferase (New England Biolabs, Beverly, Massachu-
setts, United States) was used as the methylated control. In a
subset of cases, promoter methylation was determined and/or
veriﬁed by directly sequencing PCR products of bisulﬁte-
treated genomic DNA using published primers and methods
[31]. Methylation data from a subset of patients has been
previously reported [31].
DNA Sequencing
Genomic or primer extension preampliﬁcation DNA was
sequenced using either BigDye or BigDyeV3 Terminator cycle
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United States) on either an ABI 377, ABI 3730, or ABI 3700
DNA sequencer. Wild-type sequences for each participant
were conﬁrmed using constitutive samples. All mutations
were conﬁrmed by at least two independent PCR and
sequencing reactions and, in cases of ambiguity, by direct
sequencing of genomic DNA. Evaluation of mutation of exons
5–9 of the TP53 gene was performed on 1,118 ﬂow-puriﬁed
fractions under conditions described previously [56]. TP53
mutations from patients with HGD were reported by Prevo et
al. [56], and additional new TP53 mutations not previously
reported are available from the corresponding author (PCG).
Mutation analysis of exon 2 of the CDKN2A gene was
performed in 1,109 ﬂow-puriﬁed fractions, detailed by
Paulson 2006 (unpublished data) and with methods described
previously [31].
Use of Aspirin and Other NSAIDs
Questionnaires and methods for determining host varia-
bles were as described previously [25] and were available for
241 participants. Use of aspirin and other NSAIDs in the
current study was deﬁned in the same way as NSAID use,
including NSAID use in follow-up, as described in Vaughan et
al. [25]. Brieﬂy, duration and frequency of regular aspirin and
NSAID use were assessed, with ‘‘regular’’ deﬁned by use at
least once per week for  6 mo. The NSAID variable took into
account changes in aspirin and NSAID medication use during
the follow-up period. It has been shown previously that there
are no signiﬁcant differences between the protective associ-
ations of aspirin and other NSAIDs in this cohort [25].
Patients were classiﬁed as being users (including patients who
were regular aspirin or other NSAID users within 1 y of the
baseline interview or at any time during follow-up, n ¼ 157),
or nonusers (former users or those who had never used
NSAIDs, n ¼ 84).
Statistical Analysis
We sought to evaluate the extent to which speciﬁc tissue-
based, mechanistically derived molecular markers, both alone
and in combination, predict risk of progression to EA in
patients with BE. The analytic approach is summarized as
follows. (1) Univariate Cox proportional hazard analyses (not
adjusted for host variables or other markers) were used to
determine the EA risk of patients with each marker,
measured at baseline at 2-, 6-, and 10-y follow-up time points
(Table 2). (2) Stepwise multivariate Cox regression was used to
select, from among all of the available molecular markers, a
subset which independently contributes to EA risk prediction
(Table 3). (3) Cumulative EA incidence and relative risk (RR)
of progression to EA at 10 y were calculated for patients with
different numbers of the selected markers at baseline relative
to patients with no abnormalities (Table 4). To determine the
contribution of known or suspected nongenetic host factors
to EA risk prediction, we incorporated these host factors
together with all molecular markers in a multivariate Cox
model. Only NSAID use showed signiﬁcant independent
prediction in combination with molecular markers in this
multivariate model. The predictive ability of the selected
molecular markers was evaluated among NSAID users and
nonusers (Figures 1 and 2).
Two hundred and forty-three patients had informative
data for all of the molecular markers (17p LOH, TP53
mutation, tetraploidy, aneuploidy, 9p LOH, and CDKN2A
mutation). Except for CDKN2A methylation, all markers in
Table 2. Univariate Analysis of RR for EA during Follow-up
Baseline Variable Variable Status Number Cumulative Number EA and Percentage at Different Follow-up Times
2 y 6 y 10 y
17p LOH No LOH 196 3 (1.5%) 7 (3.6%) 13 (6.6%)
LOH 47 11 (23.4%) 20 (42.6%) 21 (44.7%)
Univariate RR (95% CI) 17.8 (5.0–63.9) 16.3 (6.9–38.7) 10.6 (5.2–21.3)
TP53 mutation No mutation 210 7 (3.2%) 12 (5.7%) 19 (9.0%)
Mutation 33 7 (21.2%) 15 (45.5%) 15 (45.5%)
Univariate RR (95% CI) 7.2 (2.5–20.5) 10.8 (5.0–22.3) 7.3 (3.7–14.3)
Tetraploidy Normal 219 7 (3.2%) 15 (6.8%) 21 (9.6%)
4n . 6% 24 7 (29.2%) 12 (50.0%) 13 (54.2%)
Univariate RR (95% CI) 10.9 (3.8–31) 10.3 (4.8–22.0) 8.8 (4.3–17.7)
Aneuploidy Diploid 214 5 (2.3%) 14 (6.5%) 20 (9.3%)
Aneuploid 29 9 (31.0%) 13 (44.8%) 14 (48.3%)
Univariate RR (95% CI) 16.5 (5.5–49.4) 10.5 (4.9–22.4) 8.5 (4.3–17.0)
9p LOH No LOH 98 1 (1.0%) 3 (3.1%) 7 (7.1%)
LOH 145 13 (9.0%) 24 (16.6%) 27 (18.6%)
Univariate RR (95% CI) 8.9 (1.2–67.9) 5.6 (1.7–18.5) 2.6 (1.1–6.0)
CDKN2A methylation
a Unmethylated 49 1 (2.0%) 1 (2.0%) 3 (6.2%)
Methylated 72 8 (11.1%) 15 (20.8%) 16 (22.2%)
Univariate RR (95% CI) 1.2 (1.1–9.2) 3 (1.4–6.4) 2.1 (0.8–4.1)
CDKN2A mutation No mutation 206 12 (5.8%) 21 (10.2%) 26 (12.6%)
Mutation 37 2 (5.4%) 6 (16.2%) 8 (21.6%)
Univariate RR (95% CI) 0.93 (0.2–4.2) 1.7 (0.7–4.2) 1.8 (0.8–4.1)
Cumulative number EA 14 27 34
aOne hundred and twenty-one patients were analyzed for methylation (see Methods).
doi:10.1371/journal.pmed.0040067.t002
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each participant. CDKN2A methylation status was coded as
yes, no, or no data in the statistical model because only 121
patients had sufﬁcient quantity of DNA to be evaluated for
this marker. In the Cox regression models for molecular
marker selection, the statistical signiﬁcance levels used in the
initial process of stepwise selection for variable entry and
removing were 0.25 and 0.15, respectively. Based on initial
selection results, p ¼ 0.05 was used as the signiﬁcance
threshold for the ﬁnal selection (second Cox model).
Association relationship among binary markers was also
assessed using coefﬁcient U. The Kaplan-Meier method was
used to estimate the probability of EA in different stratiﬁed
groups. The Gehan-Wilcoxon test was used to test differences
in the cancer incidence curves. The Grambsch-Therneau test
was used to examine the signiﬁcance of a change in RR ratio
over time for all markers. We adjusted p-values for multiple
comparisons in Figure 2 using the Benjamini and Hochberg
method [57]. All of the analyses were performed with
Statistical Analysis System (SAS) software Version 9.0; (SAS
Institute, http://www.sas.com).
Results
Univariate Analysis of LOH, Mutation, Methylation,
Tetraploidy, and Aneuploidy for EA Risk Prediction
The cohort characteristics for participants used for
molecular and DNA content analysis are shown in Table 1.
During the follow-up period of this study, 34 participants
developed EA. The number of participants with each genetic
abnormality at baseline and the cumulative number who
developed cancer at 2, 6, and 10 y are shown in Table 2. The
risk of EA during follow-up in patients with each molecular
and DNA content abnormality was assessed with univariate
analysis using Cox regression models (2, 6, and 10 y presented
to show general trend, Table 2). The RRs presented in Table 2
were not adjusted for host variables, but the signiﬁcance of
the results does not change when such adjustments are
performed. At 10 y, each molecular and DNA content
abnormality, when analyzed alone in a patient at baseline,
made a signiﬁcant contribution to prediction of EA risk, with
the exception of CDKN2A mutation (10-y RR ¼ 1.8; 95% CI
0.8–4.1, p¼0.13) and CDKN2A methylation (RR¼2.1; 95% CI
0.8–4.1, p ¼ 0.09). For example, the univariate RRs ranged
from a high for 17p LOH (10-y RR¼10.6; 95% CI 5.2–21.3, p
, 0.001) to that for 9p LOH (10-y RR¼2.6; 95% CI 1.1–6.0, p
¼ 0.03). Although RRs at intermediate time points may be
unstable owing to small numbers, 9p LOH had a higher RR at
early follow-up intervals. The RR in univariate analysis for 9p
LOH was 8.9 (95% CI 1.2–67.9, p¼ 0.04) at 2-y follow-up, but
decreased to RR ¼ 2.6 by 10 y. With the current dataset, 9p
LOH was the only abnormality that showed a statistically
signiﬁcant change in RR over time (nonproportional hazard
over time, p¼0.004, Grambsch-Therneau test for global trend
at 10 y).
Comprehensive Analysis of Relationships among the
Multiple Molecular Abnormalities for EA Risk Prediction
To determine a set of biomarkers that are independent
predictors of EA risk, baseline molecular markers were
evaluated using multivariate Cox models with backward and
forward stepwise selection. Starting with all molecular
abnormalities for selection, 17p LOH was the most signiﬁcant
abnormality selected by the statistical model, and remained a
strong predictor when accounting for TP53 mutation status
in a step-wise analysis process. Although TP53 mutation was
highly signiﬁcant in univariate analysis, it became non-
signiﬁcant for EA risk prediction when 17p LOH was
included in the model. Tetraploidy was the next selected
marker, followed by aneuploidy. Finally, 9p LOH improved
the model for risk prediction signiﬁcantly in combination
with 17p LOH and DNA content abnormalities (likelihood
ratio test p ¼ 0.03). CDKN2A methylation provided marginal
additional risk but was not statistically signiﬁcant in the
multivariate model (p ¼ 0.28). CDKN2A mutation did not
provide signiﬁcant additional contribution to EA risk
prediction. The ﬁnal selected molecular markers that
Table 3. Stepwise Selection for Molecular Markers and RR for EA
of Final Selected Markers
Order of Being
Selected in
Stepwise Selection
Final Selected
Markers
Final Model
RR (95% CI)
Final Model
p-Value
1 17p LOH 5.4 (2.5–12.0) ,0.001
2 Tetraploidy 2.9 (1.4–5.9) ,0.001
3 Aneuploidy 3.4 (1.6–7.1) 0.001
4 9p LOH 2.4 (1.0–5.5) 0.045
doi:10.1371/journal.pmed.0040067.t003
Table 4. Cumulative EA Incidence and RR of Different Baseline Abnormality Combinations
Marker Cumulative EA Incidence (Number of EA Cases) RR (95% CI) p-Value
2y 6y 1 0y
No abnormalities (n ¼ 85) 0% (0) 0% (0) 12% (3) Base for RR calculations
One abnormality (n ¼ 104)
a 0.96% (1) 5.65% (5) 19.88% (8) RR 1.8 (0.48–6.87), p . 0.38
Two abnormalities (n ¼ 32)
b 16.83% (5) 28.40% (8) 35.56% (9) RR 9.0 (2.4–33.3), p , 0.001
Three abnormalities (n ¼ 22)
c 40.20% (8) 79.12% (14) (14)
d RR 38.7 (10.8–138.5), p , 0.001
a17p LOH (n ¼ 4); DNA content abnormality (n ¼ 2); 9p LOH (n ¼ 98).
b17p LOH and DNA content abnormality (n ¼ 7); 17p LOH and 9p LOH (n ¼ 14); 9p LOH and DNA content abnormality (n ¼ 11).
c17p LOH and DNA content abnormality and 9p LOH.
dOwing to insufficient data, incidence not estimated.
doi:10.1371/journal.pmed.0040067.t004
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17p LOH, tetraploidy, aneuploidy, and 9p LOH (Table 3). To
further evaluate the associations among the markers, we
calculated the association coefﬁcient (U) for all binary
markers. TP53 mutation showed strong association with 17p
LOH (U ¼ 0.63) and aneuploidy (U ¼ 0.56). 17p LOH is also
strongly associated with aneuploidy (U ¼ 0.56). No other
strong associations were observed by this method. Although
TP53 mutation was signiﬁcantly related to EA risk in
univariate analysis, it was strongly associated with 17p LOH
and aneuploidy, which may explain why it was not retained in
the model selection. The adjusted RRs for future EA at 10 y,
using the ﬁnal selected model with 17p LOH, tetraploidy,
aneuploidy, and 9p LOH, were RR¼5.4 (95% CI 2.5–12.0), RR
¼2.9 (95% CI 1.4–5.9), RR¼3.4 (95% CI 1.6–7.1), and RR¼2.4
(95% CI 1.0–5.5), respectively (Table 3).
Effect of Combinations of Selected Panel Abnormalities on
Cumulative EA Incidence
Each study participant had the potential to have any
combination of selected panel abnormalities at baseline.
Stratiﬁcation by all possible combinations of the selected
abnormalities was limited by an inadequate number of
patients for analysis in some strata, and we therefore grouped
participants based on the number of abnormalities at
baseline. Table 4 lists the cumulative EA incidence at 2, 6,
and 10 y, and the RR at maximum follow-up (10 y) for future
development of EA for participants with no panel abnormal-
ities, a single abnormality (either 17p LOH, any DNA content
abnormality, or 9p LOH), any two selected abnormalities, or
all three selected abnormalities at baseline. Tetraploidy and
aneuploidy are two measures of DNA content and were
treated as a single variable in this section (Figures 1 and 2;
Table 4). Study participants with no baseline abnormalities
(85/243) remained cancer free to almost 8 y (95 mo) and had a
relatively low 10-y cumulative cancer incidence of 12%. In
participants with only a single baseline abnormality (104/243),
the 6-y EA incidence was 5.65%, with an overall 10-y EA
incidence of 19.88%. It is of note that 9p LOH was the single
abnormality in 98/104 of those participants, indicating that it
was rare for 17p LOH or a DNA content abnormality to be
detected alone. Participants with two abnormalities detected
at baseline (32/243) had increasing cumulative EA incidence
of 16.83%, 28.4%, and 35.56% at 2, 6, and 10 y, respectively,
showing a signiﬁcantly higher EA risk than for patients with
no abnormalities at baseline (RR ¼ 9.0; 95% CI 2.4–33.3, p ,
0.001). Participants (22/243) with all three abnormalities (17p
LOH, DNA content abnormality, and 9p LOH) had EA
incidence rates of 40.2% and 79.12% at 2 and 6 y,
respectively. Owing to sample size, the EA incidence rate at
the 10-y time point was not estimated. These patients had the
highest risk of cancer relative to those with a no baseline
abnormalities (RR ¼ 38.7; 95% CI 10.8–135.5, p , 0.001). Of
these cancer cases, 80% occurred within 36 mo, and all
Figure 1. Modulation of EA Risk by NSAIDs in Participants with Different Baseline Abnormalities
Two hundred and forty-one patients are classified according to whether they have (A) baseline 17p LOH (n ¼ 46), (B) baseline DNA content
abnormalities (aneuploidy and/or tetraploidy) (n¼41), (C) baseline 9p LOH (n¼144), or (D) more than one baseline abnormality (top two curves) or one
or less abnormality (lower two curves). Shown are Kaplan-Meier curves of cancer incidence rates in patients who are NSAID nonusers (former or never
users, red curves) or NSAID users (current or user during follow-up, black curves).
doi:10.1371/journal.pmed.0040067.g001
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NSAIDs Modulate Biomarker Panel for EAFigure 2. Cumulative EA Incidence with Combinations of Abnormalities (17p LOH, DNA Content Abnormality, 9p LOH) in NSAID Nonusers and NSAID Users
Cancer incidence rates are shown for participants with no selected abnormalities (17p LOH, DNA content abnormalities [aneuploidy and/or tetraploidy],
or 9p LOH) at baseline (red), any one abnormality (green), any combination of two abnormalities (blue), or all three abnormalities (black). (A) All
participants. When comparing NSAID nonusers (B) and NSAID users (C) there is a strong significant trend toward EA risk reduction in the NSAID users
group for all abnormality combinations (Mantel-Haenszel test p ¼ 0.01).
doi:10.1371/journal.pmed.0040067.g002
PLoS Medicine | www.plosmedicine.org February 2007 | Volume 4 | Issue 2 | e67 0348
NSAIDs Modulate Biomarker Panel for EAcancers that developed in patients with three baseline
abnormalities did so within a 55-mo follow-up period.
Association of NSAID Use with Reduction of EA Risk in
Participants with 17p LOH, DNA Content Tetraploidy and
Aneuploidy, and 9p LOH
Multiple nongenetic host factors and demographic varia-
bles have been previously suggested as potential modiﬁers of
EA progression including age, gender, waist-to-hip ratio,
smoking status, segment length, and NSAID use [24,58–67].
To determine the host variables that provide independent
prediction for EA when combined with molecular markers,
we incorporated these nongenetic host factors with all
molecular markers into a new Cox model for variable
selection. The selected independent variables were 17p
LOH, DNA content abnormalities (tetraploidy and aneu-
ploidy), 9p LOH, and NSAID use. In combination with the
selected molecular abnormalities, NSAID use was associated
with a statistically signiﬁcant reduction of EA risk (p , 0.001).
Thus, NSAID use was evaluated as a potential modulator of
cancer risk in combination with selected genetic abnormal-
ities. For a given selected molecular marker, Kaplan-Meier
analysis showed that NSAID use during follow-up provided a
signiﬁcant association with protection against development
of EA, relative to participants who were NSAID nonusers
(former or never) (Figure 1). This protective effect was
signiﬁcant in patients with baseline 17p LOH (p ¼ 0.004,
Gehan-Wilcoxon test), DNA content abnormalities (tetra-
ploidy and/or aneuploidy) (p ¼ 0.01), and 9p LOH (p ,0.001)
(Figure 1A–C). For patients with more than one panel
abnormality at baseline, NSAID use was associated with a
signiﬁcant reduction in EA incidence (p ¼ 0.001): NSAID
nonusers had an observed cumulative EA risk of 68%,
compared to 30% for NSAID users at 6 y, and 79% compared
to 30% for NSAID users at 10 y (Figure 1D). In participants
with either no abnormalities or one abnormality at baseline
(predominantly 9p LOH, Table 4), cancer risk was low, and
the protective effect of NSAIDs for future EA was not
signiﬁcant (p ¼ 0.28 at 10-y follow-up).
EA Incidence in NSAID Nonusers and NSAID Users
Stratified by Combinations of Baseline Abnormalities
Cancer incidence of all participants based on the overall
number of select panel abnormalities at baseline is shown in
Kaplan-Meier curves (Figure 2A). When comparing NSAID
nonusers (Figure 2B, n¼84) and NSAID users (Figure 2C, n¼
157) within all categories (zero, one, two, or three abnormal-
ities at baseline), there was a strong signiﬁcant trend toward
EA risk reduction in the NSAID user’s group (Mantel-
Haenszel test p ¼ 0.01). NSAID nonusers with two or three
abnormalities at baseline had a highly signiﬁcant increased
EA incidence compared to NSAID nonusers with zero or one
lesion (two versus zero p , 0.001; two versus one p ,0.001;
three versus zero p , 0.001; three versus one p , 0.001;
adjusted for multiple comparisons with Benjamini and
Hochberg method [57] [Figure 2B]). All other comparisons
for NSAID nonusers, for example between participants with
two versus three abnormalities, were nonsigniﬁcant. Partic-
ipants who used NSAIDs regularly (Figure 2C) and had all
three abnormalities at baseline had a signiﬁcantly increased
cumulative EA incidence compared to NSAID users with zero,
one, and two abnormalities (p , 0.001, p , 0.001, and p ¼
0.045, respectively). NSAID users with two baseline abnor-
malities had a signiﬁcant or marginally signiﬁcant increased
cancer incidence relative to NSAID users with zero or one
abnormality (p ¼ 0.013 and p ¼ 0.07, respectively).
Discussion
This investigation reports the results of a prospective
cohort study of mechanistic-based genetic abnormalities
evaluated as predictors of EA and demonstrates the modulat-
ing effect of NSAIDs on EA risk in patients with BE. We
hypothesized that a panel of somatic genetic abnormalities
involving TP53, CDKN2A, and DNA content could improve
prediction of progression to EA and that NSAID use may
modulate EA risk. In this longitudinal study spanning more
than a decade, we showed that a combination of 17p LOH, 9p
LOH, and DNA content tetraploidy and aneuploidy provide
signiﬁcant, independent EA risk prediction. NSAID use is
associated with reduction of EA risk, and the protective effect
was highly signiﬁcant for patients who have multiple high-risk
molecular abnormalities at baseline. These analyses include
34 EA endpoints, which is second only to our previous 15-y
report of histology and ﬂow cytometry (42 EAs) and
substantially larger than most other longitudinal studies of
biomarkers in BE from other centers, which have typically
reported 12 or fewer incident cancers [41,42,68,69]. This
prospective study has been conducted in a single center with
a high-risk cohort; studies in other centers will be required to
determine whether our results can be generalized to other
patient populations and to validate the results for clinical
application. Our results are consistent, however, with
previous longitudinal studies of single biomarkers from other
centers, including TP53 abnormalities and ﬂow cytometry
[41,42,70]. To our knowledge, no previous studies in patients
with BE or any other human premalignant condition have
prospectively evaluated the contributions of TP53 and
CDKN2A gene inactivation (methylation, mutation, and
LOH) and DNA content abnormalities in combination with
candidate interventions to assess their potential utility as
biomarkers for future cancer risk and cancer prevention.
The mechanisms by which TP53 and CDKN2A regulate the
cell cycle under normal and abnormal conditions have been
investigated extensively in elegant molecular studies in vitro
and in model organisms. Perturbations of these genes and the
pathways in which they act have profound, mechanistic
associations with human cancer based upon evidence
accumulated in numerous laboratories [1,71–75]. In BE,
neoplastic progression is characterized by clonal evolution
in which genetic instability generates variants on which
natural selection acts, resulting in waves of clonal expansion,
generation of new variants, and further selection [76,77].
TP53 abnormalities typically arise in clones with CDKN2A
abnormalities [78], creating a condition permissive for clonal
variants, including tetraploid and aneuploid populations, to
survive and expand [79]. Thus, the abnormalities in this
biomarker panel assess viable clones that undergo expansion
(CDKN2A) and survive chromosomal instability (TP53, DNA
content). Assessment of multiple stages of clonal evolution
may be the basis for improved risk stratiﬁcation compared to
single biomarkers.
We simultaneously measured DNA content abnormalities
(tetraploidy and aneuploidy), inactivation of TP53 (mutation
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ation, and LOH), all of which have been shown to be
mechanistically related to neoplastic progression in BE
[28,29,34,80–82]. TP53 abnormalities have been shown in
numerous studies to be predictive of EA [41,70,83–85]. In the
present study, TP53 mutations were strongly associated with
17p LOH and aneuploidy and were not selected in the
multivariate analysis. Selection of LOH over methylation or
mutation in the Cox model could occur because LOH is a
common manifestation of the chromosomal instability that is
characteristic of neoplastic progression in BE [29]. LOH
could also be selected as the ‘‘second hit’’ for inactivating
TP53 and CDKN2A. Alternatively, LOH events often span
large chromosomal regions that could include other genes
such as HIC1 (17p13.3) [86] and p14
ARF (9p21) [72,87] that may
confer additional selective advantages over mutational or
methylation events that affect only TP53 and CDKN2A.
Recently, Maley et al. reported that clonal diversity measures
derived from evolutionary biology retained signiﬁcant
independent EA risk prediction with 17p (TP53) LOH and
abnormal ploidy, but 9p LOH became nonsigniﬁcant when
incorporating evolutionary variables [88]. The nonpropor-
tional hazard varying with time that we found for 9p LOH in
the present study may reﬂect the genetic background of the
CDKN2A clone. For example, expansion of a CDKN2A
abnormal clone that is otherwise genetically stable may
homogenize the neoplasm, minimizing diversity on which
natural selection might act to promote progression [76,77]. In
contrast, expansion of a CDKN2A abnormal clone predis-
posed to genetic instability through either environmental or
somatic genetic factors would result in increased diversity
that could promote progression.
Although this study had a large number of EA endpoints
for published studies of BE, the number of cancers was
relatively small compared to studies in breast and colon, for
example. Therefore, estimates of RR over time showing the
9p LOH nonproportional hazard over time need to be
further investigated in future studies. In addition, RR for EA
presented in Table 2 at intermediate follow-up times should
be treated with caution. We do not recommend that
clinicians manage patients on these data alone. Within the
BE research ﬁeld, there is a paucity of data concerning
progression to EA in patients with different molecular
abnormalities. We present the intermediate time points to
inform design of future intervention and multicenter studies,
while maintaining statistical rigor in our analyses.
Identiﬁcation of host genetic factors, including inherited,
highly penetrant mutations in cancer susceptibility for
hereditary breast cancer (BRCA1, BRCA2), familial polyposis
coli (APC), and those predisposing to hereditary non-
polyposis colon cancer, among others, in combination with
knowledge of environmental factors, have the potential to
reduce cancer morbidity and mortality by early detection and
prevention [5,6,9,10,89–91]. In contrast to inherited muta-
tions in relatively uncommon susceptibility genes, less is
known concerning temporal progression of somatic genetic
abnormalities in more prevalent sporadic premalignant
conditions. Genetic progression models have been proposed
for many types of cancers based largely on cross-sectional
data [11,13,14,92–104]. TP53, CDKN2A, and DNA content
(tetraploidy and aneuploidy) abnormalities are among the
most common abnormalities in cancers and premalignant
conditions affecting multiple organs, including head and
neck, lung, breast, bladder, and pancreas, among others [1,71–
73]. Few data exist as to their ability to predict future cancer
or how these lesions can be modulated by chemoprevention
efforts. Advances have been made in cancer risk prediction
for patients with oral premalignant lesions in multiple
retrospective, longitudinal studies [13–16]. Lee et al. com-
bined multiple biomarkers and patient characteristics in Cox
regression analysis and found that chromosome polyploidy,
together with high p53 expression, LOH, and histology was
the best predictor of cancer risk in a 10-y study of 70 patients
with 22 cancer outcomes [13]. Thus, genetic progression
models may be a rich source of hypotheses for retrospective
longitudinal and prospective biomarker validation studies.
In experimental model systems and observational studies,
aspirin and other NSAIDs have been reported to inhibit
cyclo-oxygenase 2, increase apoptosis, decrease inﬂammation,
decrease proliferation, and inhibit angiogenesis [4,26,27,105–
111]. It has recently been shown that the absolute size of
aneuploid clones and clones with TP53 lesions is a risk factor
for progression to EA [79]. NSAIDs may act by reducing clone
size through increasing apoptosis and decreasing angio-
genesis and proliferation. By increasing apoptosis, NSAIDs
may decrease the generation of viable clones, thus decreasing
diversity and limiting the pool of genetic variants on which
natural selection may act. In addition, NSAIDs function to
reduce inﬂammation, which may in turn reduce the mutation
rate in evolving clones and decrease the number of cellular
variants. The cohort analyzed in the present report is a subset
of that described in Vaughan et al. [25]. Of the molecular
cohort described in the present study, 65% were current
NSAID users—including use in follow-up—and this propor-
tion is comparable with the 63% regular NSAID users
(including use in follow-up) in the total cohort. About half
of the users took aspirin for reasons concerning cardiovas-
cular health, and the vast majority of the other users
primarily took ibuprofen for pain relief. In a previous paper,
we reported a strong protective association for EA with
current NSAID use (at baseline or during follow-up), a rather
rapid diminution of the association among former users, and
no evidence of a stronger association with increasing
frequency and/or duration of use. Furthermore, we did not
ﬁnd signiﬁcant differences in risk of EA or aneuploidy
according to type of NSAID. Thus for the present report, our
patients were classiﬁed simply as NSAID user or nonuser
(former or never) based on use at least once per week for  6
mo any time during follow-up, regardless of daily frequency,
duration, or type. By focusing on the salient results from the
previous analyses of a larger dataset regarding NSAIDs, we
avoided multiple comparisons and could focus on the
relationship of NSAID use with the status of molecular
abnormalities.
Our results show a protective association between NSAID
use and progression to EA in all participants, and particularly
among those with multiple somatic genetic abnormalities.
The vast majority of patients in this cohort had gastro-
esophageal reﬂux disease and were undergoing therapy,
predominately using proton pump–inhibitors, to reduce
reﬂux symptoms. It is unclear as to how the frequency or
severity of symptoms may affect NSAID use by participants.
However, to our knowledge, symptoms from reﬂux are not
associated with intermediate endpoints or cancer in BE, so it
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NSAID use with reduced risk of EA. None of the patients had
endoscopically visible concomitant conditions of the stom-
ach, such as ulcers, at the baseline endoscopy that could have
conceivably altered NSAID use. Given the experimental
evidence provided in model systems and in previous studies,
we propose that NSAIDs act within the BE tissue to modulate
progression to EA. Our study is early translational research,
as deﬁned by the National Cancer Institute Translational
Research Working Group (http://www.cancer.gov/aboutnci/
trwg/presentations). These results advance our understanding
of the molecular mechanisms of neoplastic progression as
well as the mechanisms by which aspirin and other NSAIDs
may prevent cancer. As such, these results are consistent with
the National Institutes of Health goals of prevention,
prediction, and personalized medicine. Several other types
of research will be essential for these results to reach the
clinic: multicenter randomized trials with a mechanistic focus
to determine the effects of aspirin or other NSAIDs on
progression to EA and intermediate endpoints (high-risk
biomarkers), health services research to evaluate the effect of
the interventions as well as the cost effectiveness of
biomarkers that reduce frequencies of endoscopy and
numbers of biopsies, and establishment of reimbursement
mechanisms to support dissemination and adoption (Na-
tional Cancer Institute’s translational continuum; http://www.
cancer.gov/trwg/TRWG-deﬁnition-and-TR-continuum).
Our study builds on a body of observational research, a
recent meta-analysis, and supportive data in other cancers,
most notably colon cancer where several clinical trials have
reported a protective association of aspirin and other
NSAIDs, although some ﬁndings have been inconsistent
[9,10,21–25,89–91,112–116]. The present study extends these
ﬁndings by evaluating the association of NSAID use with
somatic genetic events that deﬁne progression in BE and
demonstrates the beneﬁts of NSAID use in patients at high
risk of progressing to EA. Our results are consistent with
previous results showing a protective effect on the part of
NSAIDs in patients with HGD [25], and with computer
models indicating that high-risk patients are the most likely
to beneﬁt from NSAID intervention [117]. The incidence of
EA is sufﬁciently low in BE that designing statistically
rigorous, adequately powered prevention studies with cancer
as an endpoint is not feasible for most research cohorts. Thus,
knowledge of the interaction of NSAIDs and somatic genetic
abnormalities will help deﬁne entry criteria for randomized
intervention trials with a cancer endpoint. The combination
of a somatic genetic biomarker panel that identiﬁes those
patients with BE who are at high risk of progression to EA,
combined with an inexpensive, widely available, and relatively
safe means of preventing neoplastic progression in such high-
risk patients, could have signiﬁcant public health and
economic beneﬁts.
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Background. Normally, the cells in the human body divide only when
extra cells are needed, after an injury, for example. Sometimes, however,
cells accumulate genetic changes (mutations) that allow them to divide
uncontrollably to form a disorganized mass or tumor. If these altered
cells also acquire mutations that allow them to spread around the body,
a malignant tumor or cancer results. Scientists have identified numerous
genetic changes that occur in tumors and are now investigating whether
these molecular abnormalities can be used as ‘‘biomarkers’’ to choose
the best treatments for patients, to identify who will benefit from cancer-
prevention strategies, to detect cancer early, and to predict which
cancers are most likely to become life-threatening. This last application is
particularly important for cancers with a well-defined premalignant
stage. Because the cells in premalignant tissues have acquired some of
the genetic changes required for cancer development, they are more
likely to become malignant than normal cells. Barrett’s esophagus, for
example, is a premalignant disorder of the muscular tube that takes food
from the mouth to the stomach. People with Barrett’s esophagus are
much more likely to develop esophageal cancer than the general
population.
Why Was This Study Done? Esophageal cancer is often incurable by the
time it is detected, so it would be helpful to know which people with
Barrett’s esophagus are most likely to develop esophageal cancer—only
1 in 200 of them develop cancer each year. In this study, the researchers
evaluated whether a panel of genetic alterations could identify this
subset of patients. They also investigated whether the regular use of
aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) affects
the risk of developing esophageal cancer in people with Barrett’s
esophagus—other evidence suggests that NSAIDs may help to prevent
several types of cancer, including esophageal cancer.
What Did the Researchers Do and Find? The researchers took
esophageal tissue samples from patients with Barrett’s esophagus and
looked for alterations in the genes encoding the tumor-suppressor
proteins TP53 and CDKN2A. These proteins normally stop cells dividing
but are often inactivated in cancer cells by mutation of one of the two
gene copies that encode each of them and also loss of the other copy
(so-called ‘‘loss of heterozygosity’’ or LOH). The researchers also looked
for changes in the cellular DNA content of the samples (tumor cells often
contain unusual amounts of DNA) and asked the study participants
about their NSAID use before waiting to see which participants
developed esophageal cancer. After 10 y, the participants whose tissue
samples had LOH of the short arms (p) of Chromosome 17 or 9 (the sites
of the genes encoding TP53 and CDKN2A, respectively), or an altered
DNA content, were more likely to have developed esophageal cancer
than those without these abnormalities; those whose samples contained
all three abnormalities had the highest risk of developing esophageal
cancer. Overall, just 12% of patients with no abnormalities but nearly
80% of patients with three abnormalities developed esophageal cancer.
NSAID use reduced the risk of cancer development in all the participants,
but its effect was greatest in those with three genetic abnormalities.
What Do These Findings Mean? These findings suggest that the
combined measurement of 17pLOH, 9pLOH, and cellular DNA content
might be a powerful way to identify those patients with Barrett’s
esophagus who are most likely to develop esophageal cancer. They also
suggest that NSAID use is associated with a reduced risk of esophageal
cancer, particularly in patients with multiple genetic abnormalities.
Because very few participants developed cancer during the study, these
results need confirming in more patients. Also, the ability of NSAIDs to
prevent the progression of Barrett’s esophagus to esophageal cancer
needs testing in multicenter randomized trials; the use of the panel of
abnormalities described here to identify the people with Barrett’s
esophagus most at risk of developing esophageal cancer should facilitate
such studies.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040067.
  CancerQuest information from Emory University (Atlanta, Georgia,
United States) on cancer biology, including the role of tumor
suppressor proteins
  US National Cancer Institute patient and physician information on
esophageal cancer and its prevention
  MedlinePlus encyclopedia pages on Barrett’s esophagus and
esophageal cancer
  Cancerbackup (UK charity) patient information on esophageal cancer
and Barrett’s esophagus
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